Gilead Sciences' simtuzumab failed to meet its main goal in a Phase II pancreatic cancer trial, denting the potential of a therapy the company hopes can treat a wide range of malignancies.
Aduro BioTech's GVAX, a previously failed cancer vaccine, is finding new life in a combination treatment that the Berkeley-based company is testing in patients with pancreatic cancer.
Aduro BioTech joined the short list companies outside Big Pharma to pick up the FDA's coveted breakthrough therapy designation, impressing the agency with strong mid-stage results for its combo cancer therapy.
Patients with pancreatic cancer whose disease still persists after regular treatments may benefit from a new cancer drug nanoliposome formulation, according to a presentation at the European Society for Molecular Oncology's 16th World Congress on Gastrointestinal Cancer.
Halozyme is back on track with a midstage trial of its in-development pancreatic cancer treatment after the FDA lifted its clinical hold on enrollment, news that sent the company's shares up as much as 20%.
Are you healthy? Do you have pancreatic cancer, pancreatitis or pancreatic cysts? In early testing, Texas researchers successfully used four blood biomarkers that aided in early-stage diagnosis to help tell the difference.
The latest news sliced only 3% off the biotech's share price.
Halozyme has pressed pause on a Phase II trial of its lead cancer candidate over safety concerns, news that sent the biotech's shares down 25% on Friday morning.
A pair of biotechs will proceed with cancer vaccine studies thanks to recent recommendations from data-monitoring committees. Their announcements drew mixed results from investors, with Northwest Biotherapeutics' shares soaring and NewLink Genetics' sinking. But as they forge ahead, both companies will have to shake off the looming specters of failed cancer vaccine trials past.
After an interim analysis, NewLink Genetics is planning to keep on keeping on with a Phase III study of its cancer vaccine. But that news came as an apparent disappointment to investors, who hoped the drug's promise would result in an early trial termination, and the biotech's shares fell more than 12% on Friday morning.